

1 **Multi-site clinical validation of Isothermal Amplification based SARS-COV-2 detection assays**
2 **using different sampling strategies**

3
4 Kanan T. Desai¹, Karla Alfaro², Laura Mendoza³, Matthew Faron⁴, Brian Mesich⁴, Mauricio
5 Maza², Rhina Dominguez⁵, Adriana Valenzuela³, Chyntia Díaz Acosta³, Magaly Martínez³, Juan C.
6 Felix⁴, Rachel Masch^{2,6}, Sofia Gabrilovich⁷, Michael Plump⁷, Akiva P. Novetsky^{7,8}, Mark H.
7 Einstein^{7,8}, Nataki C. Douglas⁷, Miriam Cremer^{2,9}, Nicolas Wentzensen¹

8
9 **Affiliations**

10
11 ¹Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, USA

12 ²Basic Health International, Pittsburgh, USA

13 ³Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción, San
14 Lorenzo, Paraguay

15 ⁴Medical College of Wisconsin, Milwaukee, USA

16 ⁵Research Unit, El Salvador National Institute of Health (INS), El Salvador

17 ⁶The Mount Sinai Hospital, New York, USA

18 ⁷Rutgers New Jersey Medical School, Newark, USA

19 ⁸Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

20 ⁹Cleveland Clinic Lerner College of Medicine, Cleveland, USA

21

22 **Corresponding author**

23

24 Kanan T. Desai

25 Clinical Genetics Branch

26 Division of Cancer Epidemiology and Genetics

27 National Cancer Institute, NIH, USA

28 Email: kanan.desai@nih.gov

29

30

31 **Abstract (Limit: 250; Current:250)**

32

33 Background:

34 Isothermal amplification-based tests were developed as rapid, low-cost, and simple alternatives
35 to real-time reverse transcriptase-polymerase chain reaction (RT-PCR) tests for SARS-COV-2
36 detection.

37 Methods:

38 Clinical performance of two isothermal amplification-based tests (Atila Biosystems iAMP
39 COVID-19 detection test and OptiGene COVID-19 Direct Plus RT-LAMP test) was compared to
40 clinical RT-PCR assays using different sampling strategies. A total of 1378 participants were
41 tested across four study sites.

42 Results:

43 Compared to standard of care RT-PCR testing, the overall sensitivity and specificity of the Atila
44 iAMP test for detection of SARS-CoV-2 were 76.2% and 94.9%, respectively, and increased to
45 88.8% and 89.5%, respectively, after exclusion of an outlier study site. Sensitivity varied based
46 on the anatomic collected site. Sensitivity for nasopharyngeal was 65.4% (range across study
47 sites:52.8%-79.8%), mid-turbinate 88.2%, saliva 55.1% (range across study sites:42.9%-77.8%)
48 and anterior nares 66.7% (range across study sites:63.6%-76.5%). The specificity for these
49 anatomic collection sites ranged from 96.7% to 100%. Sensitivity improved in symptomatic
50 patients (overall 82.7%) and those with a higher viral load (overall 92.4% for $ct \leq 25$). Sensitivity
51 and specificity of the OptiGene Direct Plus RT-LAMP test, conducted at a single study-site, were
52 25.5% and 100%, respectively.

53 **Conclusions**

54 The Atila iAMP COVID test with mid-turbinate sampling is a rapid, low-cost assay for detecting
55 SARS-COV-2, especially in symptomatic patients and those with a high viral load, and could be
56 used to reduce the risk of SARS-COV-2 transmission in clinical settings. Variation of
57 performance between study sites highlights the need for site-specific clinical validation of these
58 assays before clinical adoption.

59

60 **Keywords**

61

62 COVID-19, SARS-COV-2, Isothermal Amplification, clinical validation, cancer screening

63

64

65 **Main text (Limit:3000 excluding material-methods; Current: Total: 504+1988=2492 exclusive**
66 **of material-methods)**

67

68 **Introduction**

69 The COVID-19 (Coronavirus Disease of 2019) pandemic has led to major disruptions in health
70 services worldwide. In many developed nations, widespread SARS-CoV-2 (Severe acute
71 respiratory syndrome coronavirus 2) testing and mass vaccination has allowed for a return to
72 most elective health services. However, many low- and middle- income countries (LMICs) have
73 limited access to testing and vaccination and continue to struggle to contain COVID-19 (1) (2).
74 As the COVID-19 crisis continues , considerable reductions of cancer screening, cancer control,
75 and elective clinical services remain (3). The safe return to cancer screening and elective
76 testing and procedures during the pandemic, especially in low vaccination regions, requires
77 reliable SARS-CoV-2 testing for both providers and patients.

78

79 Numerous SARS-CoV-2 detection assays have been developed and introduced into the market
80 under emergency use authorizations (EUA) (4). EUAs are granted primarily based on analytic
81 sensitivity (i.e., Limit of Detection (LOD)) and analytic specificity (i.e., cross-reactivity) with
82 limited clinical validations. Yet, a thorough clinical performance evaluation of SARS-CoV-2
83 assays is important to understand the strengths, limitations, and specific applications of these
84 assays (5). Current Centers for Disease Control (CDC) guidelines recommend the use of
85 laboratory-based nucleic acid amplification test (NAAT) (e.g., reverse transcriptase-
86 polymerase chain reaction (RT-PCR)) for confirmatory testing. Specimens that are considered

87 optimal for detection include nasopharyngeal (NP), nasal mid-turbinate, and anterior nasal
88 swabs. Currently, the CDC does not recommend NAAT that use oral specimens (e.g., saliva) for
89 confirmatory testing (6–8).

90
91 In addition to clinical performance, several other factors are important to consider when
92 assessing feasibility of an assay for use in different environments and clinical settings. These
93 factors include time to run the assay, hands-on time, throughput, ease of implementation, and
94 cost. Furthermore, the possibility to use different sampling approaches, including self-
95 collection, can be an important distinguishing feature since many LMICs have limited personal
96 protective equipment (PPE). While RT-PCR assays fulfill the desired clinical performance criteria,
97 they are not ideal for primary care clinics in resource-limited settings as point-of-care SARS-
98 COV-2 screening tests due to high costs as well as longer turn around times and need for
99 technical expertise (9). While rapid antigen-based tests address these limitations, they lack
100 sensitivity to rule out an active infection (10). Isothermal amplification-based reverse
101 transcription assays may fill this gap as they are more rapid (take ~ 1 hour), cheaper (~5-15
102 USD per test) and simpler (not needing RNA extraction) than RT-PCR based tests (11), but
103 require clinical validation.

104
105 The primary objective of this study was to evaluate the clinical performance and operational
106 characteristics of two isothermal amplification-based SARS-CoV-2 tests: 1) iAMP COVID-19
107 detection test (Atila BioSystems, USA) targeting N and ORF1a-genes of SARS-COV-2 virus, and 2)
108 COVID-19 Direct Plus RT-LAMP test (OptiGene Ltd., UK) targeting ORF1ab-gene of SARS-COV-2

109 virus, compared to clinical RT-PCR tests. The secondary objective was to evaluate the influence
110 of different sampling strategies on the detection of SARS-COV-2. One specific use for such
111 assays is rapid SARS-COV-2 testing to allow for a safer return to preventive clinical encounters
112 such as cancer screening in low- and middle-income countries.

113

114 **Materials and Methods**

115

116 Study design and population

117

118 A cross-sectional study was conducted from December 2020 to April 2021 at four clinical sites:
119 Hospital Nacional de Santa Ana, El Salvador; Hospital Materno Infantil de San Lorenzo,
120 Ministerio de Salud Pública (MSP-BS), Paraguay; Medical College of Wisconsin (MCW), USA; and
121 Rutgers New Jersey Medical School (NJMS), USA (Table 1). The study protocol and sampling
122 strategies varied slightly across the study sites, based on local requirements.

123

124 At the El Salvador site, 900 asymptomatic and symptomatic subjects presenting for SARS-COV-2
125 testing were enrolled. A standard NP swab for RT-PCR was collected from all the participants for
126 clinical diagnosis. A second provider-collected dry NP swab and a self-collected direct saliva
127 sample were obtained from study participants in parallel for the Atila iAMP test.

128

129 At the Paraguay site, 265 asymptomatic and symptomatic subjects presenting for SARS-COV-2
130 testing were enrolled in the study. A standard NP swab for RT-PCR was collected from all the

131 participants for clinical diagnosis. In addition, for those consenting to participate in the study, a
132 leftover of the clinical NP swab placed in viral transport medium (VTM) and a second parallel
133 self-collected direct saliva sample were obtained for the Atila iAMP test.

134
135 At the Wisconsin (MCW) site, 128 symptomatic and asymptomatic subjects presenting for
136 SARS-COV-2 testing were enrolled in the study. A standard NP swab for RT-PCR was collected
137 from all the participants for clinical diagnosis. In addition, for those consenting to participate, a
138 second provider-collected dry NP swab, a self-collected dry mid-turbinate swab, a self-collected
139 dry anterior nares swab, and a self-collected direct saliva sample were obtained in parallel for
140 Atila iAMP test.

141
142 At the New Jersey (NJMS) site, 55 symptomatic SARS-COV-2 positive patients, based on a prior
143 RT-PCR assay, who were admitted for observation and management of COVID-19 were enrolled
144 in the study. 28 of 55 (50.9%) of the patients were enrolled within 24 hours, 14 of 55 (25.5%)
145 within 48 hours, and 6 of 55 (10.9%) within 72 hours of the sample collection for the RT-PCR
146 test. In addition, 30 participants expected to be negative for the SARS-COV-2 infection (i.e., no
147 SARS-COV-2 symptoms) were enrolled. A negative SARS-COV-2 RT-PCR test obtained within five
148 days of test sample collection was performed on 28 (93.3%) of these 30 participants. Regardless
149 of the RT-PCR status, for everyone enrolled in the study, a provider-collected dry NP swab and a
150 provider-collected dry anterior nares swab was obtained at the time of enrollment for the Atila
151 iAMP test. In addition, a provider-collected oropharyngeal (OP) swab placed in Sigma Virocult®

152 medium (MSW, UK) and a self-collected direct saliva sample was also obtained at the time of
153 enrollment for the OptiGene Direct Plus RT-LAMP test.

154

155 The study protocol at all the sites was approved by the respective local institutional ethical
156 review boards.

157

158 Test and RT-PCR assays

159

160 All the assays were performed as per the manufacturer's instruction for use (IFU).

161

162 The Atila iAMP test was performed on the same day of test sample collection for all samples in
163 El Salvador, and 81 of 85 (95.3%) samples in New Jersey (NJMS). The samples not tested on the
164 same day were frozen at -20°C in Paraguay and -80°C in Wisconsin (MCW) and tested in
165 batches. A validated RT-PCR system (i.e., Biorad CFX96 RT system or Atila PowerGene 9600 Plus
166 RT-PCR system) with FAM/HEX fluorescence detection was used for reaction run and detection.
167 Positive and negative controls were run for each batch, and the batch was considered valid only
168 if both controls were valid. The individual sample test result was determined to be positive if an
169 exponential amplification curve with cycle threshold (ct)<50 was present in the FAM (ORF-1a/b
170 or N-genes) channel. The test result was determined to be negative if the FAM channel did not
171 have an amplification curve, and the HEX (internal control) channel had an exponential
172 amplification curve with ct<50. The test was determined invalid if no amplification was
173 detected in both FAM and HEX channels, in which case the test was repeated. If the repeat run

174 was also invalid, then the that sample was considered invalid. In total, 1.0% of NP, 1.4% of
175 anterior nares, 3.9% of mid-turbinate, and 0% of saliva samples had invalid results. Less than
176 1% (0.6%) of saliva samples could not be tested secondary to the samples being predominantly
177 phlegm.

178
179 With few exceptions [5 of 85 (6.0%)], the OptiGene Direct Plus RT-LAMP test was performed on
180 the same day of the test sample collection. A Genie® III or II platform (OptiGene, UK) was used
181 for the reaction run and detection. Positive and negative controls were run for each batch of
182 samples, and the batch was considered valid only if both controls were valid. The Genie®
183 software automatically analyzed the individual sample test results as positive or negative based
184 on the amplification plot and annealing temperature. The test result is reported positive if the
185 fluorescence level of the amplification curve rises above a defined threshold and the peak of
186 the annealing curve is above a defined threshold and lies within a specified temperature range.
187 All of the OP and anterior nares samples were tested. 19% of the saliva samples were not
188 tested because those samples were predominantly phlegm without saliva.

189
190 A single run was performed for each sample at all study sites except at NJMS which performed
191 duplicate runs for each sample. To ensure comparability across the sites, for the pooled
192 analysis, the first of the duplicate run at NJMS was used.

193

194 Statistical analysis

195

196 Pooled and study site-specific analyses were performed overall and stratified by different
197 sampling strategies. For the overall analysis, if any sample anatomic collection site tested
198 positive, that subject was identified as positive for that test assay. If all collection site samples
199 were negative for the subject, the subject was considered negative for that test assay.

200

201 The NP sample for the RT-PCR test used for clinical diagnosis was considered the reference
202 method. The sensitivity was defined as the proportion of RT-PCR positive samples which tested
203 positive by the test assay, and specificity was defined as the proportion of the RT-PCR negative
204 samples which tested negative by the test assay. Additional stratified analyses by the ct-value
205 for the RT-PCR, as a surrogate marker for the viral load, and history of symptoms were also
206 performed wherever the data was available. History of symptoms was collected from the
207 subjects at the time of sample collection. 95% confidence intervals (CI) were calculated for the
208 sensitivity and specificity measures. Imbalances in paired sample results were evaluated using
209 Mc-Nemar's test, with a p-value <0.05 considered statistically significant. Data analysis was
210 performed using IBM® SPSS software.

211

212 **Results**

213

214 Atila iAMP test

215

216 In the overall analysis (Figure 1), the sensitivity of the Atila iAMP test was 76.2% (95% CI: 71.1-
217 80.7) and the specificity was 94.9% (95% CI: 93.3-96.1) for detection of SARS-CoV-2. Stratified

218 by study site, the sensitivity was 63.8% (95% CI: 55.9-71.2) in El Salvador, 88.5% (95% CI: 79.9-
219 94.3) in Paraguay, 88.9% (95% CI: 65.3-98.6) in Wisconsin, and 89.1% (95% CI: 77.8-95.9) in New
220 Jersey. The specificity was 97.2% (95% CI: 95.7-98.2), 81.3% (95% CI: 74.7-86.7), 100% (95% CI:
221 96.6-100) and 100% (95% CI: 88.4-100), respectively. Since the El Salvador site's sensitivity was
222 significantly lower than all the other sites, and considered an outlier, we conducted an overall
223 pooled analysis excluding El Salvador, which demonstrated an overall sensitivity of 88.8% (95%
224 CI: 82.8-93.2) and an overall specificity of 89.5% (95% CI: 85.6-92.7).

225
226 We evaluated the clinical performance of individual sampling strategies (Figure 2). The
227 sensitivity and specificity of the provider-collected NP sample was 65.4% (95% CI: 59.9-70.6)
228 and 97.6% (95% CI: 96.5-98.4). Since sensitivity at the El Salvador site was significantly different
229 than all the other sites, we recalculated the overall sensitivity excluding El Salvador, which led
230 to the sensitivity of 78.9% (95% CI: 71.6-85.1) and specificity of 95.4% (95% CI: 92.4-97.5).

231
232 Comparing the other sampling strategies to the reference standard NP sample, self-collected
233 dry mid-turbinate sample (only collected at MCW) was found to be most sensitive [88.2% (95%
234 CI: 63.6-98.5)] and specific [100% (95% CI: 96.5-100)]. Self-collected saliva samples, excluding El
235 Salvador (due to significantly different estimate than other sites), had an overall sensitivity of
236 74.5% (95% CI: 64.9-82.6) and overall specificity of 91.8% (95% CI: 87.9-94.7). The self-collected
237 dry anterior nares sample was the least sensitive strategy with the overall sensitivity of 66.7%
238 (95% CI: 54.6-77.3) and overall specificity of 100% (95% CI: 97.3-100). Since anterior nares
239 sample was not collected at the El Salvador study site and none of the study sites had

240 significantly different estimate than other sites for anterior nares sample, no exclusion was
241 made.

242
243 Assuming that viral load would influence accuracy, we analyzed the sensitivity at different ct-
244 values on RT-PCR among the positive subjects (Figure 3). Restricting the analysis to samples
245 with $ct \leq 35$, $ct \leq 30$, $ct \leq 25$, and $ct \leq 20$ increased the sensitivity to 82.6%, 97%, 100% and 100% for
246 NP samples and 68%, 86.1%, 88.9%, and 100% for anterior nares samples in New Jersey (NJMS)
247 and 79.8%, 81.3%, 88.4%, and 100% for NP samples and 73.8%, 73.8%, 79.7%, and 84.3% for
248 saliva samples in Paraguay. The respective corresponding percentages for El Salvador were
249 65.9%, 78.1%, 83.6%, and 89.1% for NP samples and 52.8%, 58.3%, 64.4% and 65.5% for saliva
250 samples. Although the sensitivity increased in El Salvador with an increase in viral load (i.e. at
251 lower ct-values), within each ct-value strata, the sensitivity in El Salvador was still lower than in
252 Paraguay and New Jersey for each anatomic collection sites.

253
254 The mean ct-value on RT-PCR in El Salvador among the RT-PCR positive asymptomatic subjects
255 was 30.0 (95% CI: 25.6-30.4), and among symptomatic subjects was 22.5 (95% CI: 20.2-24.8).
256 The respective corresponding values in Paraguay were 18 (95% CI: 13.7-22.4) and 17.5 (95% CI:
257 15.8-19.2). The mean ct-value on RT-PCR in New Jersey among the RT-PCR positive subjects was
258 25.7 (95% CI: 23.9-27.5); all RT-PCR positive subjects were hospitalized for observation and
259 management of COVID-19 and so likely symptomatic. The sensitivity of the NP sample in El
260 Salvador among symptomatic subjects was significantly higher [65.1% (95% CI: 54.1-75.1)] than
261 among asymptomatic subjects [39.0% (95% CI: 28.0-50.8)] (Figure 4). The difference was not

262 significant between symptomatic and asymptomatic subjects for NP samples in Paraguay, saliva
263 in El Salvador, and saliva in Paraguay. Among the symptomatics subjects, the sensitivity was
264 significantly higher for saliva samples in Parguay [74.3% (95% CI: 62.4-84.0)] than in El Salvador
265 [51.2% (95% CI: 40.1-62.1)]; the difference was not significant for the NP samples in Paraguay
266 [81.7% (95% CI: 70.7-89.9)] and New Jersey [78% (95% CI: 64-88.5)] and in El Salvador [65.1%
267 (95% CI: 54.1-75.1)]. Among the asymptomatic subjects, the difference for either NP [69.2%
268 (95% CI: 38.6-90.9) in Paraguay and 39% (95% CI: 28.0-50.8) in El Salvador] or saliva samples
269 [71.4% (95% CI: 41.9-91.6) in Paraguay and 33.8% (95% CI: 23.4-45.4) in El Salvador] was not
270 significantly different between Parguay and El Salvador.

271

272 OptiGene Direct Plus RT-LAMP test

273

274 The overall sensitivity and specificity of the OptiGene Direct Plus RT-LAMP test were 25.5%
275 (95% CI: 14.7-39) and 100% (95% CI: 88.4-100), respectively (Figure 5). The estimates did not
276 differ significantly by different sampling strategies or duplicate testing. Furthermore, when
277 limiting the analysis to test samples collected within 24 hrs of RT-PCR sample collection, the
278 overall sensitivity was still only 33.3%.

279

280 **Discussion**

281

282 The current study evaluated the clinical performance of two isothermal amplification tests for
283 detection of SARS-CoV-2. The overall sensitivity and specificity of the Atila iAMP test for

284 detection of SARS-CoV-2, excluding the outlier study site, were 88.8% and 89.5%, respectively.
285 The sensitivity, excluding the outlier study site, was 78.9% for nasopharyngeal, 88.2% for self-
286 sampled mid-turbinate, 74.5% for direct saliva and 66.7% for anterior nares samples. The
287 specificity for these sites ranged from 91.8% to 100%. The sensitivity increased with higher viral
288 load (i.e., at lower ct-values) and among symptomatic as compared to asymptomatic
289 participants. The sensitivity and specificity of the OptiGene Direct Plus RT-LAMP test, conducted
290 at a single site, were 25.5% and 100%, respectively.

291
292 There is scant literature on the performance of the Atila iAMP COVID test. We identified only
293 one clinical performance evaluation of the Atila iAMP COVID test on the direct, non-extracted
294 samples, which is the recommended application as per EUA by the manufacturer. This small-
295 scale evaluation (n=197) showed a sensitivity of 44.1% and specificity of 96.6% for the Atila
296 iAMP test on NP swabs with a large number (35.5% or 70/197) of invalid results (12). A small
297 (n=50) analytic and clinical validation study on the Atila iAMP assay showed the analytic LOD
298 for the assay to be 50-100 copies/reaction for ORF1-a/b gene and 1-10 for the N gene, which is
299 higher than that of RT-PCR (average range of 1-10) (13). This may explain our finding of lower
300 clinical sensitivity of the assay at higher ct-values, considering ct-values as a surrogate marker
301 for the viral load, which may not always be precise (14). In the clinical validation by the same
302 group, the assay was found to have 100% agreement with the RT-PCR. However, this validation
303 was on extracted RNA and was based on 46/50 samples that have $ct \leq 30$. Another small (n=50)
304 clinical validation (15), again on extracted RNA, showed the sensitivity and specificity of the
305 assay to be 82.8% and 100%, respectively, with all five false-negative samples to have $ct \geq 35$.

306

307 The OptiGene Direct Plus RT-LAMP COVID assay has been previously clinically validated by the
308 NHS trust to have a sensitivity of 70% for swabs and 79% for saliva, with an increase in
309 sensitivity to 100% for swabs at $ct \leq 25$ (16). However, similar to our validation, such high
310 sensitivity was not confirmed by other groups, which showed the sensitivity in the range of
311 46.7% (17) and 34%, including false-negative results on symptomatic high viral load subjects
312 (18). Our validation study was based on kits purchased from the manufacturer, using fresh
313 samples (not freeze-thawed samples) collected and placed in the VTM recommended by the
314 manufacturer, and run as per the instructions provided by the manufacturer. Furthermore,
315 even though the reference RT-PCR used in our assay targeted E or N2 and S gene in addition to
316 the ORF1-a/b gene, given that a NP swab based RT-PCR is the accepted reference standard for
317 the SARS-COV-2 diagnosis (7,8), we believe that clinical sensitivity of the assay should not be
318 affected by the differences in gene targets between the assays. While it has been suggested
319 that assays targeting the N gene are not a valid reference standard to evaluate the OptiGene
320 Direct Plus RT-LAMP assay (19), this is not supported by clinical studies.

321

322 It is important to note that the IFU's for both assays state the need to confirm the negative test
323 result with a more sensitive RT-PCR test, and do not claim to be the final screening answer (20).
324 However, as compared to the RT-PCR assays, which may sometimes take >24 hr of turnaround
325 time (TOT) with considerable cost, the isothermal amplification-based assay's advantage is its
326 rapid TOT (~1 hour), lower cost, and ease of performance (no nucleic acid extraction needed).
327 Thus, it can cheaply and rapidly identify high viral load subjects who are likely to be most

328 infectious (21)(22). Moreover, there is at least some evidence to suggest that RT-PCR positivity
329 does not necessarily translate into infectivity because it can detect the shedding of post-
330 infectious viral RNA particles shedding, particularly among post-symptomatic patients (23,24).
331 The Atila iAMP has similar advantages as the rapid antigen tests with regard to ease of
332 operability and quick TOT, but provides higher sensitivity (reported to be 67-73% for rapid
333 antigen test (25,26)) resulting in more reassurance of a negative test result.

334

335 Variation in the performance of both the assays across various study sites in our evaluation and
336 notable differences to other studies cannot be ignored. It demonstrates the limitations of EUAs
337 which may not necessarily translate to acceptable clinical performance for all tests in all
338 settings. A thorough clinical validation of diagnostic assays on a standardized panel of samples
339 in clinical settings is advisable before its widespread adoption for clinical use.

340

341 We do not fully understand the reason for the variation in test performance across study-sites.
342 Importantly, the populations at each site was different with respect to SARS-CoV-2 prevalence,
343 clinical symptoms, and other factors, but stratified analyses showed similar performance at all
344 sites except for El Salvador. Given that invalid results were rare and did not differ across the
345 study sites and there was no consistent pattern observed in ct-values for the internal control
346 [mean ct-values for the internal control for NP: 28.4 (95% CI: 28.1-28.7) (El Salvador), 34.1 (95%
347 CI: 32.8-35.1) (MCW), 22.7 (21.9-23.4) (Paraguay), 25.4 (23.4-27.3) (NJMS); for saliva: 19.4 (95%
348 CI: 19.1-19.7), 23.6 (95% CI: 23.1-24.2) (MCW), 22.1 (21.3-22.8) (Paraguay)], we do not attribute
349 the lower sensitivity in our validation in El Salvador to sampling variation. Rather we

350 hypothesize the lower sensitivity of the Atila iAMP test in El Salvador to be related to multiple
351 factors: relatively higher proportion of asymptomatic subjects as compared to Paraguay (69.8%
352 versus 21.9%) and operator-dependent nature of the assay due to the hands-on nature of the
353 test to set up the reaction (27). However, given that on stratified analysis by symptoms and ct-
354 values, the sensitivity was still lower in El Salvador than other sites within the strata, makes the
355 second explanation more likely. Variation in the reference standard RT-PCR method and RNA
356 extraction kits used across the study sites as well as variation in duration of performing the test
357 assay after collection is a limitation of our study and may also have influence on the study site-
358 wide variations.

359

360 **Conclusions**

361

362 In this first large-scale multi-site clinical evaluation of the Atila BioSystems iAMP COVID-19
363 detection test, the assay showed good sensitivity with high specificity for detection of SARS-
364 CoV-2, particularly on high viral load (i.e., $ct \leq 25$) NP samples. In addition, it also showed
365 moderate sensitivity for $ct \leq 35$ NP samples and $ct \leq 25$ saliva samples. Overall, the sensitivity was
366 superior for NP and mid-turbinate samples compared to saliva and anterior nares samples. The
367 rapid TOT, low cost, and lack of need for nucleic acid extraction make Atila iAMP test a
368 reasonable alternative screening test for SARS-COV-2 for patients and providers in outpatient
369 clinics to identify likely infectious subjects. When implemented with other COVID safety
370 measures, such low cost testing can provide an approach for the safe reopening and daily
371 clinical activities of essential medical services for the highest risk population in immediate need

372 of care. However, inconsistency observed in assay performance across the study sites highlights
373 the need for a rigorous site-specific clinical performance evaluation of the isothermal-
374 amplification-based assays before their clinical adoption.

375

376 **References**

- 377 1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard
378 With Vaccination Data [Internet]. [cited 2021 May 11]. Available from:
379 <https://covid19.who.int/>
- 380 2. COVID-19 Vaccine Market Dashboard | UNICEF Supply Division [Internet]. [cited 2021
381 May 11]. Available from: [https://www.unicef.org/supply/covid-19-vaccine-market-](https://www.unicef.org/supply/covid-19-vaccine-market-dashboard)
382 [dashboard](https://www.unicef.org/supply/covid-19-vaccine-market-dashboard)
- 383 3. Cancino RS, Su Z, Mesa R, Tomlinson GE, Wang J. The impact of COVID-19 on cancer
384 screening: challenges and opportunities [Internet]. Vol. 6, JMIR Cancer. JMIR Publications
385 Inc.; 2020 [cited 2021 May 11]. Available from:
386 <https://pubmed.ncbi.nlm.nih.gov/33027039/>
- 387 4. In Vitro Diagnostics EUAs - Molecular Diagnostic Tests for SARS-CoV-2 | FDA [Internet].
388 [cited 2021 May 11]. Available from: [https://www.fda.gov/medical-devices/coronavirus-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#individual-molecular)
389 [disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#individual-molecular)
390 [diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#individual-molecular](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#individual-molecular)
- 391 5. Mitchell SL, St George K, Rhoads DD, Butler-Wu SM, Dharmarha V, McNult P, et al.
392 Understanding, verifying, and implementing emergency use authorization molecular
393 diagnostics for the detection of sars-cov-2 RNA [Internet]. Vol. 58, Journal of Clinical

- 394 Microbiology. American Society for Microbiology; 2020 [cited 2021 May 11]. Available
395 from: <http://jcm.asm.org/>
- 396 6. Nucleic Acid Amplification Tests (NAATs) | CDC [Internet]. [cited 2021 May 28]. Available
397 from: <https://www.cdc.gov/coronavirus/2019-ncov/lab/naats.html>
- 398 7. A Composite Reference Standard for COVID-19 Diagnostic Accuracy Studies: a roadmap -
399 The Centre for Evidence-Based Medicine [Internet]. [cited 2021 May 14]. Available from:
400 [https://www.cebm.net/covid-19/a-composite-reference-standard-for-covid-19-
401 diagnostic-accuracy-studies-a-roadmap/](https://www.cebm.net/covid-19/a-composite-reference-standard-for-covid-19-
401 diagnostic-accuracy-studies-a-roadmap/)
- 402 8. Laboratory testing of 2019 novel coronavirus (2019-nCoV) in suspected human cases:
403 interim guidance, 17 January 2020 [Internet]. [cited 2021 May 14]. Available from:
404 [https://www.who.int/publications/i/item/laboratory-testing-of-2019-novel-coronavirus-
405 \(-2019-ncov\)-in-suspected-human-cases-interim-guidance-17-january-2020](https://www.who.int/publications/i/item/laboratory-testing-of-2019-novel-coronavirus-
405 (-2019-ncov)-in-suspected-human-cases-interim-guidance-17-january-2020)
- 406 9. Favresse J, Gillot C, Oliveira M, Cadrobbi J, Elsen M, Eucher C, et al. Head-to-Head
407 Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-
408 CoV-2 Infection. *J Clin Med* [Internet]. 2021 Jan 13 [cited 2021 May 11];10(2):265.
409 Available from: </pmc/articles/PMC7828347/>
- 410 10. Interim Guidance for Antigen Testing for SARS-CoV-2 | CDC [Internet]. [cited 2021 May
411 28]. Available from: [https://www.cdc.gov/coronavirus/2019-
412 ncov/lab/resources/antigen-tests-guidelines.html#table1](https://www.cdc.gov/coronavirus/2019-
412 ncov/lab/resources/antigen-tests-guidelines.html#table1)
- 413 11. COVID-19 – AtilaBiosystems [Internet]. [cited 2021 May 11]. Available from:
414 <https://atilabiosystems.com/our-products/covid-19/>
- 415 12. Ganesan S. Evaluation of seven different rapid methods for nucleic acid detection of

- 416 SARS-COV-2 virus 2 Running title: Rapid methods for nucleic acid detection of SARS-COV-
417 2 virus [Internet]. Preprint on medRxiv. [cited 2021 May 14]. Available from:
418 <https://doi.org/10.1101/2021.04.15.21255533>
- 419 13. SARS-CoV-2 molecular assay evaluation: results - FIND [Internet]. [cited 2021 May 14].
420 Available from: [https://www.finndx.org/covid-19/sarscov2-eval-molecular/molecular-](https://www.finndx.org/covid-19/sarscov2-eval-molecular/molecular-eval-results/)
421 [eval-results/](https://www.finndx.org/covid-19/sarscov2-eval-molecular/molecular-eval-results/)
- 422 14. Ct Values: What They Are and How They Can be Used • Version 2 • Is there variability in
423 Ct values? 2021;
- 424 15. Bulterys PL, Garamani N, Stevens B, Sahoo MK, Huang CH, Hogan CA, et al. Comparison
425 of a laboratory-developed test targeting the envelope gene with three nucleic acid
426 amplification tests for detection of SARS-CoV-2. J Clin Virol [Internet]. 2020 Aug 1 [cited
427 2021 May 14];129. Available from: <https://pubmed.ncbi.nlm.nih.gov/32535398/>
- 428 16. Rapid evaluation of OptiGene RT-LAMP assay (direct and RNA formats) - GOV.UK
429 [Internet]. [cited 2021 May 14]. Available from:
430 [https://www.gov.uk/government/publications/rapid-evaluation-of-optigene-rt-lamp-](https://www.gov.uk/government/publications/rapid-evaluation-of-optigene-rt-lamp-assay-direct-and-rna-formats/rapid-evaluation-of-optigene-rt-lamp-assay-direct-and-rna-formats)
431 [assay-direct-and-rna-formats/rapid-evaluation-of-optigene-rt-lamp-assay-direct-and-rna-](https://www.gov.uk/government/publications/rapid-evaluation-of-optigene-rt-lamp-assay-direct-and-rna-formats/rapid-evaluation-of-optigene-rt-lamp-assay-direct-and-rna-formats)
432 [formats](https://www.gov.uk/government/publications/rapid-evaluation-of-optigene-rt-lamp-assay-direct-and-rna-formats/rapid-evaluation-of-optigene-rt-lamp-assay-direct-and-rna-formats)
- 433 17. Iacobucci G. Covid-19: Rapid test missed over 50% of positive cases in Manchester pilot.
434 BMJ. 2020 Nov 6;371:m4323.
- 435 18. Wilson-Davies ESW, Mahanama AIK, Samaraweera B, Ahmed N, Friar S, Pelosi E.
436 Concerns regarding the sensitivity of the OptiGene direct SARS-CoV-2 LAMP assay and its
437 suitability for use in at-risk groups and hospital staff [Internet]. Vol. 82, Journal of

- 438 Infection. W.B. Saunders Ltd; 2021 [cited 2021 May 14]. p. 282–327. Available from:
439 [/pmc/articles/PMC7870105/](#)
- 440 19. Fowler DV, Douglas DA, Godfrey PK, Williams PA, Beggs PA, Kidd S, et al. Critical
441 evaluation of the methodology used by Wilson-Davies et al., (2020) entitled “Concerning
442 the Optigene Direct LAMP assay, and it’s use in at-risk groups and hospital staff.” Vol. 82,
443 Journal of Infection. W.B. Saunders Ltd; 2021. p. 282–327.
- 444 20. Direct RT-LAMP for Hospital Screening | The BMJ [Internet]. [cited 2021 May 14].
445 Available from: <https://www.bmj.com/content/371/bmj.m4323/rr-1>
- 446 21. Sohni Y. Variation in LOD Across SARS-CoV-2 Assay Systems: Need for Standardization.
447 Lab Med. 2021 Mar 15;52(2):107–15.
- 448 22. Jefferson T, Spencer EA, Brassey J, Heneghan C. Viral cultures for COVID-19 infectious
449 potential assessment – a systematic review. Clin Infect Dis [Internet]. 2020 Dec 3 [cited
450 2021 May 14]; Available from: <https://pubmed.ncbi.nlm.nih.gov/33270107/>
- 451 23. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological
452 assessment of hospitalized patients with COVID-2019. Nature [Internet]. 2020 May 28
453 [cited 2021 May 14];581(7809):465–9. Available from:
454 <https://pubmed.ncbi.nlm.nih.gov/32235945/>
- 455 24. Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of
456 SARS-CoV-2. BMJ [Internet]. 2020 Oct 23 [cited 2021 May 14];371. Available from:
457 <http://dx.doi.org/10.1136/bmj.m3862>
- 458 25. Favresse J, Gillot C, Oliveira M, Cadrobbi J, Elsen M, Eucher C, et al. Head-to-Head
459 Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-

- 460 CoV-2 Infection. J Clin Med [Internet]. 2021 Jan 13 [cited 2021 May 14];10(2):265.
461 Available from: [/pmc/articles/PMC7828347/](https://pubmed.ncbi.nlm.nih.gov/33939481/)
- 462 26. Stovitz SD. In suspected SARS-CoV-2, rapid antigen detection tests had 67% to 73%
463 sensitivity and 98% to 100% specificity. Ann Intern Med [Internet]. 2021 May 4 [cited
464 2021 May 14]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33939481>
- 465 27. Crozier A, Rajan S, Buchan I, McKee M. Put to the test: Use of rapid testing technologies
466 for Covid-19. BMJ [Internet]. 2021 Feb 3 [cited 2021 May 14];372. Available from:
467 <http://dx.doi.org/10.1136/bmj.n208>
468

469 **Table 1: Description of the study population**

Descriptors		El Salvador	Paraguay	Wisconsin	New Jersey N/Total (%)	
		N/Total (%)	N/Total (%)	N/Total (%)	Atila	Optigene
Type of PCR (reference) test	Abbott® RealTime SARS-COV-2 assay (Abbott, USA) targeting RdRp and N-genes	900/900 (100.0%)	0	0	0	
	Cobas® SARS-COV-2 assay (Roche Diagnostics, USA) targeting ORF-1a/b and E-genes	0	0	128/128 (100.0%)	0	
	STAT-NAT® COVID-19 MULTI assay (Sentinel	0	265/265 (100.0%)	0	0	

	Diagnostics, Italy) targeting RdRP and ORF1b-genes				
	Xpert Xpress SARS- COV-2 assay (Cepheid®, USA) targeting N2 and E- genes	0	0	0	14/85# (16.5%)
	Simplexa™ COVID-19 Direct assay (DiaSorin Molecular, USA) targeting ORF-1ab and S-genes	0	0	0	50/85# (58.8%)

	Quest Diagnostics lab-developed test (LDT)	0	0	0	1/85 [#] (1.2%)
PCR (reference) result	Positive	163/900 (18.1%)	87/264 (33.0%)	18/126 [^] (14.1%)	55/85 (64.7%)
PCR (reference) result by ct-values	<=20	57/163 (35.0%)	54/87 (62.1%)	N/A	10/55 [#] (18.2%)
	21-25	17/163 (10.4%)	20/87 (23.0%)		20/55 [#] (36.4%)
	26-30	24/163 (14.7%)	9/87 (10.3%)		7/55 [#] (12.7%)
	31-35	26/163 (16.0%)	4/87 (4.6%)		14/55 [#] (25.5%)
	>=36	39/163 (23.9%)	0		2/55 [#] (3.6%)
Duration between sample collection for PCR (reference) and test assay	Parallal (Same day)	900/900 (100.0%)	265/265 (100.0%)	128/128 (100.0%)	8/85 (9.4%)


Duration between sample collection for test assay and running the assay		Same day	900/900 (100.0%)	0	N/A		81/85 (95.3%)	80/85 (94.1%)				
Sample collection sites		Nasopharyngeal	900	900	265	258	128	123	79	78	0	0
Total sample collected	Total sample with valid result	Saliva***	900	900	265	259**	128	126*	0	0	84	68*
		Anterior Nares***	0	0	0	0	128	126	85	84	85	85
		Mid-turbinate***	0	0	0	0	127	122	0	0	0	0
		Oropharyngeal	0	0	0	0	0	0	13	11	71	71
Age (years)		18-28	204/900 (22.7%)		118/265 (44.5%)		N/A		N/A			
		29-39	242/900 (26.9%)		74/265 (27.9%)							
		40-50	222/900 (24.7%)		41/265 (15.5%)							

	>=51	232/900 (25.8%)	32/265 (12.1%)		
Gender	Male	425/900 (47.2%)	106/265 (40.0%)	N/A	N/A
	Female	475/900 (52.8%)	159/265 (60.0%)		
Symptomatic	Yes	272/900 (30.2%)	207/265 (78.1%)	N/A	31/61 (50.8%)
Total		900/1378 (65.3%)	265/1378 (19.2%)	128/1378 (9.3%)	85/1378 (6.2%)

470 N/A-Data not available; *All invalid runs were due to insufficient sample/mainly phlegm to process; **Three samples out of six total invalid runs were due to
471 insufficient sample/mainly phlegm to process; *** saliva, mid-turbinate, and anterior nares (at Wiconsin) were self-collected, # Type of RT-PCR data not
472 available for 20 of 85 samples, Ct-values not available for 2 of 55 samples; ^RT-PCR results missing for 2 of 128 subjects.

473

474 **Figure 1: Study site specific analysis of validity of Atila iAMP assay against PCR (Reference) test (not stratified by sample collection**
475 **site)**




476

477 *P-value < 0.05 for McNemar's test (continuity corrected); **Any sample collection site positive out of the total samples collected is considered positive

478

479 **Figure 2: Study site specific analysis of validity of Atila iAMP assay against PCR (Reference) test (stratified by sample collection**
 480 **site)**




481

482

483 *P-value < 0.05 for McNemar's test (continuity corrected); #Samples were tested in duplicates and the test was considered positive only if both were positive;

484 @Samples were tested in duplicates and the test was considered positive if either was positive


485 **Figure 3: Study site and sample site specific analysis of the sensitivity of Atila iAMP assay against PCR (Reference) test stratified by**
 486 **the ct-values**



487
 488 *Sensitivity for ct < 35 and ct < 30 was equal

489

490 **Figure 4: Study site and sample site specific analysis of validity of Atila iAMP assay against PCR (Reference) test stratified by the**
491 **Symptoms**




492

493 *P-value < 0.05 for McNemar's test (continuity corrected)

494

495 **Figure 5: Study site specific analysis of validity of OptiGene Direct Plus RT-LAMP assay against PCR (Reference) test (overall and**
 496 **stratified by sample collection site)**



497

498 *P-value < 0.05 for McNemar's test (continuity corrected); **Any sample collection site positive out of the total samples collected is considered positive;

499 #Samples were tested in duplicates and the test was considered positive only if both were positive; @Samples were tested in duplicates and the test was

500 considered positive if either was positive

501

502 **Acknowledgements**

503

504 The field effort was a collaboration of the US National Cancer Institute (NCI) with Basic Health
505 International (BHI), USA and Rutgers New Jersey Medical School (NJMS), USA. The BHI had
506 collaboration with Hospital Nacional de Santa Ana, El Salvador, Hospital Materno Infantil de San
507 Lorenzo, Ministerio de Salud Pública y Binestar Social (MSP-BS), Paraguay, Centro de
508 Especialidades Dermatológicas, MSP-BS, Paraguay, Instituto de Investigaciones en Ciencias de la
509 Salud, Universidad Nacional de Asunción, Paraguay, , and Medical College of Wisconsin, USA.

510

511 **Funding**

512

513 The research was funded by the intramural NCI Cancer MoonshotSM and intramural research
514 program.

515

516 **Conflict of Interest**

517

518 The authors have nothing to declare. None of the companies had any role in design, analysis,
519 interpretation, and finalization of the manuscript.

520

521 **Author's contributions**

522

523 NW, APN, NCD, JF, MM, RM, MC, KTD contributed substantially to the conception and design of
524 the study. KA, LM, MM, RD, AV, CDA, MM, JF, MP, APN, MHE contributed to acquisition of data.
525 MF, SG, NCD, BM contributed to running the test assays. KTD, LM, NW contributed to the
526 analysis and interpretation. KTD, NW drafted the manuscript. All authors provided critical
527 revision of the article and provided final approval of the version to publish.

528

529 **Ethical approval and informed consent**

530

531 The study was approved by the ethical review board of Comité Nacional de Ética de
532 Investigación en Salud (IRB no.FWA00010986) in El Salvador, Comité de Ética, Instituto de
533 Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción (IRB no. P37/2020) in
534 Paraguay, MCW IRB (IRB no. FWA00000820) in Wisconsin, and the Newark Health Sciences IRB
535 for Rutgers Biomedical Health Sciences (IRB no. Pro2020001801) in New Jersey. Written
536 informed consent was obtained from all study participants.

537

538 **Availability of data**

539

540 The datasets used in the current study are available from the corresponding author on
541 reasonable request

542

543 **Abbreviations:**

544

545	CI	Confidence Interval
546	COVID-19	Coronavirus Disease of 2019
547	CT	Cycle Threshold
548	EUA	Emergency Use Authorization
549	iAMP	Isothermal Amplification
550	IFU	Instruction for Use
551	LAMP	Loop-mediated Isothermal Amplification
552	LMIC	Low- and Middle- Income Countries
553	LOD	Limit of Detection
554	MCW	Medical College of Wisconsin
555	NAAT	Nucleic Acid Amplification Test
556	NP	Nasopharyngeal
557	OP	Oropharyngeal
558	NJMS	Rutgers New Jersey Medical School
559	RT-PCR	Reverse Transcription-Polymerase Chain Reaction
560	SARS-COV-2	Severe Acute Respiratory Syndrome Coronavirus 2
561	SPSS	Statistical Package of Social Studies
562	VTM	Viral Transport Medium
563		
564		